VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Study sponsor: Veru Inc. · VERU
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-07-06Actual
Enrollment · participants204Actual
Source updated2026-09-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.